Cello World Q2 FY26 results: consolidated revenue up about 20%, PAT grows 5%

Results View source PDF Explain this filing

CELLO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.1%Reaction day

₹634.00

prior close

₹595.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.3%-1.8% vs market

Houseware peers, median of 6sector-1.9%-0.1% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 0.1 pts less than its Houseware peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.8

10m

+2.0

15m

+2.3

30m

+1.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.1-0.3-1.8-1.9-0.1

Next day

-3.9+0.7-4.6+0.5-4.5

-2.2+0.6-2.8-2.6+0.4

-1.3+0.5-1.8-2.3+1.0

-2.8+1.1-3.9-2.1-0.7

-3.7+0.3-4.0-2.9-0.8

-6.0-0.2-5.8-2.9-3.1

15d

-8.8-2.2-6.6+3.3-12.2

-11.8-4.9-6.9-6.9-4.9

-21.1-7.5-13.7-4.9-16.2

-19.2-4.8-14.4+3.6-22.8

UpDownMarket · Nifty Microcap 250Sector · Houseware peers, median of 6Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cello World reported Q2 FY26 consolidated revenue of Rs. 587.4 crores, up about 19.9% YoY from Rs. 490 crores. Consolidated PAT rose 5.2% to Rs. 91.3 crores. H1 FY26 revenue grew 12.7% to Rs. 1,116 crores while H1 PAT dipped 2.2% to Rs. 172 crores. Standalone Q2 revenue grew 10.3% to Rs. 275.6 crores with PAT at Rs. 23.5 crores. Auditor Deloitte issued an unqualified limited review. QIP funds utilisation report shows no deviation. Composite scheme of arrangement pending NCLT approval.

Likely market impact

Strong consolidated revenue growth from subsidiaries; PAT growth modest. NCLT scheme approval remains a key near-term catalyst to watch.